The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The Wnt/β-catenin pathway is a well-known oncogenic pathway. Its suppression has long been considered as an important challenge in treating cancer patients. Among colon cancer patients in particular, most patients carry an adenomatous polyposis coli (APC) mutation that leads to an aberration of Wnt/β-catenin pathway. To discover the small molecule inhibitors of the Wnt/β-catenin pathway, we conducted high-throughput screening in APC-mutant colon cancer DLD-1 cells using a transcriptional reporter assay, which identified a selective Wnt/β-catenin pathway inhibitor, K-756. K-756 stabilizes Axin and reduces active β-catenin, and inhibits the genes downstream of endogenous Wnt/β-catenin. We subsequently identified that K-756 is a tankyrase (TNKS) inhibitor. TNKS, which belongs to the PARP family, poly-ADP ribosylates Axin and promotes Axin degradation via the proteasome pathway. K-756 binds to the induced pocket of TNKS and inhibits its enzyme activity. Moreover, PARP family enzyme assays showed that K-756 is a selective TNKS inhibitor. K-756 inhibited the cell growth of APC-mutant colorectal cancer COLO 320DM and SW403 cells by inhibiting the Wnt/β-catenin pathway. An in vivo study showed that the oral administration of K-756 inhibited the Wnt/β-catenin pathway in colon cancer xenografts in mice. To further explore the therapeutic potential of K-756, we also evaluated the effects of K-756 in non–small cell lung cancer cells. Although a single treatment of K-756 did not induce antiproliferative activity, when K-756 was combined with an EGFR inhibitor (gefitinib), it showed a strong synergistic effect. Therefore, K-756, a novel selective TNKS inhibitor, could be a leading compound in the development of anticancer agents. Mol Cancer Ther; 15(7); 1525–34. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“As theWnt/b-catenin pathway is also important in cancer cell differentiation (45) and antitumor immunity (46), future in vivo studies may reveal other effects of a TNKS inhibitor, which cannot be detected in in vitro studies.”
BackgroundThe cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595 · cited 1×
“The hyperactivation of the Wnt/b-catenin pathway is observed in many cancers including colon, gastric, and hepatocellular cancer (12, 13).”
Backgroundβ-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628 · cited 13×
“K-756 stabilizes Axin1 and 2 by inhibiting TNKS1 and 2 Next, to examine the mechanism of action of K-756, DLD-1/ TCF-Luc cellswere treatedwithK-756 and the expressionof Axin1, Axin2, and the unphosphorylated active formofb-catenin protein were detected by Western blot analysis.”
BackgroundInfluentialGurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“Anti-Frizzled antibodies and porcupine inhibitors have already been studied in clinical trials (14, 15).”
BackgroundA Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316 · cited 3×
“The most studied TNKS inhibitor is G007-LK; however, it was administered intraperitoneally (18).”
Background
Cited by
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
Regulation of Wnt/β‐catenin signalling by tankyrase‐dependent poly(ADP‐ribosyl)ation and scaffolding
Mariotti, L., Pollock, K., & Guettler, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14038 · Cited by 144
“…IWR-2 (Chen et al., 2009; Gunaydin et al., 2012), were discovered in phenotypic screens designed to identify antagonists of the Wnt/β-catenin pathway, as were the inhibitors JW74 (Waaler et al., 2011), JW55 (Waaler et al., 2012), WIKI4 (James et al., 2012) and K-756 (Okada-Iwasaki et al., 2016).”
A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Park, W.-J., & Kim, M. J. (2023) · Cells · doi:10.3390/cells12081110 · Cited by 57
Metadata
- Authors
- Okada-Iwasaki, R., Takahashi, Y., Watanabe, Y., Ishida, H., Saito, J.-I., Nakai, R., & Asai, A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-07-01
- Volume
- 15
- Issue
- 7
- Pages
- 1525-1534
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2343619752
- Cited by
- 48
- References
- 6
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0938
- The paper
- Okada-Iwasaki, R., Takahashi, Y., Watanabe, Y., Ishida, H., Saito, J.-I., Nakai, R., & Asai, A. (2016). The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.